News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

InNexus Inc. Names Morhet As Vice President Of Operations


10/19/2005 5:12:19 PM

VANCOUVER, Nov. 29 /PRNewswire-FirstCall/ -- InNexus Biotechnology, Inc. (TSX.V: IXS) announced today it has named Jeff Morhet as Vice President of Operations.

Mr. Morhet will be responsible for leading product development and coordinating planning for clinical trials. He brings a broad range of pharmaceutical and biotechnology experience from progressive roles at Baxter Healthcare, Merck, AstraZeneca and Zila, Inc.

"We are excited to further strengthen our management team by adding someone with Jeff's extensive and unique background to our group." said Dr. Charles Morgan, President and Chief Executive Officer of InNexus. "We are confident he will bolster InNexus' operational performance as we prepare for the next stage of the company's growth."

Most recently, Morhet was Vice President and General Manager for Zila, Inc., a developer and manufacturer of biopharmaceutical products, where he re-focused and led the company's multiple clinical development, manufacturing and FDA regulatory programs. Morhet also founded and directed Zila Biotechnology, Inc., a comprehensive research, development and licensing business developing cellular and intracellular targeting therapeutics and diagnostics.

About InNexus

InNexus is developing the next generation of therapeutic, monoclonal antibodies using its SuperAntibody Technology Platform. InNexus intends to apply this technology to improve the potency of existing antibody products while opening new markets and disease applications with other forms of SuperAntibodies. InNexus is developing the technology through partnerships with biotechnology and pharmaceutical companies while pursuing development of its own products for unmet medical needs. To learn more about InNexus please visit the Company's website: http://www.innexusbiotech.com/

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not historical facts and are subject to risks and uncertainties which could cause actual results and the timing of certain events to differ materially from those set forth in or implied herein including, without limitation, risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims litigation and other risks associated with the Company's proposed activities.

On behalf of the Board of Directors of InNexus Biotechnology, Inc. "signed" Dr. A. Charles Morgan President Investor Relations: Toll-free: 1-866-990-8382 or 1-888-271-0788 investor@innexusbiotech.com The TSX Venture Exchange has neither approved nor disapproved of the information contained herein.

InNexus Biotechnology, Inc.

CONTACT: Investor Relations: Toll-free: 1-866-990-8382 or1-888-271-0788, investor@innexusbiotech.com


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES